NFE2L2 and myeloid sarcoma: DMF is a precursor of monomethyl fumarate (MMF) (Figure 2f), which has been shown to reduce the relapse rates and retard disability progression in patients with MS through activation of the nuclear translocation of Nrf2 [54,92].